The metabolic syndrome

American Journal of Cardiology

Volumn 93, Issue 2, 2004, Pages 274-

  Roberts, William Clifford ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ARTERIAL PRESSURE; BODY MASS; EDITORIAL; FAT INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; LABORATORY TEST; MEDICAL ASSESSMENT; MEDICAL RECORD; METABOLIC SYNDROME X; OBESITY; PATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0348223708     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.10.001     Document Type: Editorial

References (6)

1. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Park Y.-W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 163:2003;427-436.
3. Heymsfield S.B., Segal K.R., Hauptman J., Lucas C.P., Boldrin M.N., Rissanen A., Wilding J.P.H., Sjöström L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 160:2000;1321-1326.
4. Rössner S., Sjöström L., Noack R., Meinders A.E., Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with Orlistat for obesity. Obes Res. 8:2000;49-61.
5. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., Kostis J.B., Sheps D.S., Brinton E.A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study a randomized trial . JAMA. 284:2000;1263-1270.
6. Gagné C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 105:2002;2469-2475.